The largest differences in the FTIR spectra of the four heart chambers of NT samples were seen in the amidic bands of proteins. The RA had the highest intensity of these amidic bands. These results are in agreement with those of Pelouch et al. [22], who reported that the total protein content of the atria was greater than that of the ventricles, particularly in the right chamber. In Raman spectra of atria, an increase of intensity was observed at about 1250cm− 1 and the amide I band showed a blue shift. These two effects could be correlated with increasing collagen concentrations in the tissue [1, 14].
An amide I differentiation of atrial and ventricular Raman spectra was recently observed by Brauchle et al. [6] for murine, paraffin-embedded samples. We confirmed this observation and provided evidence of other significant differences between the two types of cardiac chambers. Our results showed higher intensity of 830cm− 1 and 903cm− 1 Raman bands in LV and RV samples. The assignment of features in the 800-1000cm− 1 spectral region is difficult, since vibrations from various chemical species contribute. For instance, in the region between 850cm− 1 and 940cm− 1, different C-C stretching modes of proline and hydroxyproline can be recognized [8]. Our observations indicated that the intensities of the 830cm− 1 and 903cm− 1 bands were strictly related, which suggested that they were due to tyrosine (tyr) vibrations [12]; it has been reported that tyr signals are always clearly visible in the Raman spectra of muscle cells [13, 28]. We estimated the ratio of the intensity of the 830cm− 1 Raman band to that of the 860cm− 1 feature. The 830-860cm− 1 couple is known as the tyr-Fermi doublet. The I830/I860 ratio has traditionally been assumed to indicate the extent of hydrogen-bonding interactions on phenolic OH; the stronger the interaction with OH as a proton-donor group, the higher the ratio [12]. Therefore, the variation in the relative intensity that we observed (Fig. 2) could be explained by a different exposure of tyr residues to the solvent followed by a conformational change of tyrosine-rich proteins, or a different degree of phosphorylation or methylation of these residues [32]. Alternatively, due to the presence of proline/hydroxyproline signals in the same spectral range, it could be related instead to a different collagen content or to a different structure of collagen fibers [8].
The Dahl/SS rat is an established model of renal and cardiovascular disease that is induced by high blood pressure when the rats are fed a HS diet [7]. Our experimental model mimics the early onset of HFpEF in its transient phase while biochemical changes in the heart are already present. Rats that were fed a HS diet exhibited a progressive increase in levels of NT-proBNP, which was, however, ascribable to ageing and not to the altered function or structure of the heart, as it did not differ from a similar increase reported in the age-matched, normal controls. The low sensitivity of this biomarker that was observed in our study is consistent with previous investigations in humans, which have shown a lack of activation of this hormone in the early phase of cardiac dysfunction and hypertension [4, 17, 18]. Thus, this humoral biomarker was not useful to detect such alterations. Moreover, while the prognostic value of NT-proBNP in HFpEF has been established, some controversy remains regarding its relevance as a diagnostic tool for this condition, due to the lower circulating levels of NT-proBNP compared with those that are found in HF with reduced ejection fraction.
Our intention was to determine cardiac biochemical fingerprints in a comprehensive medical window that ranged from the early stages of adverse cardiac remodeling to onset of HFpEF. Accordingly, we performed our analysis in Dahl/SS rats that showed signs of diastolic dysfunction after six weeks of HS diet. These signs were a moderate increase of blood pressure, increased thickness of the heart walls, enlarged LA, concentric remodeling and fibrosis. The signs of advanced HFpEF were seen in the HS22 rats and in HS16 Dahl/SS animals that showed transition from early diastolic dysfunction into HFpEF. These signs were hypertension, diastolic dysfunction and concentric hypertrophy. However, the chemical modifications described above (i.e. protein, free amino acids and tyr accumulation) were detectable at six weeks of HS diet, prior to the manifestation of canonical signs of adverse remodeling (hypertrophy, fibrosis, diastolic dysfunction, NT-proBNP elevation, etc.).
Parallel to the increases in hypertrophy and RWT, we observed robust increases of I960/I940 values in the spectra of LV and RA chambers of HT rats (Fig. 5). The 960cm− 1 Raman band was assigned to hydroxyapatite, the mineral phase that is found at the early stage of vascular calcification [19, 34]. We observed a positive correlation between the LV I960/I940 ratio and LV mass, which suggested a relationship between increased mineral deposits and increased cardiac size. The physiochemical relationship between the two warrants further investigation, in particular of the cellular or extracellular localization of the deposits. Elevated levels of Ca2+ in the resting cytosol are a feature of HFpEF [24], and vascular calcification is implicated in the development of HFpEF [9]. Our data suggest that this signal is an efficient marker of this pathological condition; therefore, it may serve as an early diagnostic tool if we consider the use of Raman spectroscopy in-vivo [10].
Recent insights have revealed the prognostic importance of LA dysfunction in HFpEF [21, 25]. While most attention has been on the remodeling of the LV, evidence suggests that events in the LA and RV contribute to HFpEF etiology. Indeed, LA dysfunction may explain the pulmonary congestion, shortness of breath, and exercise intolerance that are associated with HF. Accumulating evidence indicates that right HF is the leading cause of death in patients with HFpEF [3].
Our FTIR analysis indicated higher protein content in the RVs and LAs of HT rats compared with the controls. In addition, we also observed an intensity change at 1396cm− 1, which might be due to altered metabolism in the myocytes of HT rats that leads to an increase of free amino-acid concentration. High protein and amino-acid intakes have been inversely associated with arterial stiffness and blood pressure [26]. Thus, our results could be related to altered metabolism that leads to the accumulation of polypeptidic species at the onset of the pathological cardiovascular condition. Interestingly, the Raman findings for the I830/I860 band ratio could be correlated significantly with the histological assessment of total collagen deposition in the cardiac tissue (for both RV and LV chambers). Besides, the amide III Raman band indicated increased collagen content in samples of the RV. This evidence suggests that both tyrosine and collagen bands are efficient indicators of interstitial fibrosis.
In conclusion, this study has demonstrated the occurrence of early chemical changes (i.e. in collagen, tyrosine, protein and free amino-acid accumulation) during the evolution of HFpEF that precede the onset of canonical and often belated signs of cardiac remodeling and which are detectable with conventional diagnostic tools. Importantly, through use of FTIR and Raman spectroscopy, we are able to detect differently regulated chemical and structural changes among the four chambers of the heart and demonstrate unprecedented sensitivity and specificity. It is possible that the different pressures, and the consequent different stimulations, of the mechanosensors of the four chambers could have led to the different biochemical modifications that were observed in the atria and the ventricles. Several studies have underscored the role of mechanical force as a regulator of the structure and function of cells, tissues and organs [15]. The role of mechanosensors in the regulation of the biochemical changes is unclear and further studies are warranted. It also remains to be evaluated whether early detection of chemical alterations can provide novel therapeutic targets for the treatment of HFpEF and whether early diagnosis can lead to improved prognoses in such patients.